-

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News:

EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, notably in Idiopathic Pulmonary Fibrosis, announces that its Board of Directors meeting on November 15, 2024 has acknowledged the resignation of Enrico Bastianelli as a Director and has decided to modify its governance. Gaëtan Terrasse has been appointed Managing Director and Emmanuel Huynh Chairman. Catherine Bur remains a director.

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and meet the new needs of healthcare professionals and organizations. The company's strategy is currently focused on the clinical development of an innovative drug for Idiopathic Pulmonary Fibrosis, a chronic, devastating and fatal disease characterized by the progressive deterioration of lung function.

Contacts

EGEIRO Pharma
contact@egeiro.be

EGEIRO

BOURSE:ALVET
Release Versions
EnglishFrench

Contacts

EGEIRO Pharma
contact@egeiro.be

More News From EGEIRO

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary Fibrosis, announces that it has been informed of Euronext’s decision to classify the asset contribution of a license from H4 Orphan Pharma to TheraVet S.A. as a reverse takeover (RTO). This decision is based on two major factors: the contribution o...

TheraVet Becomes EGEIRO Pharma

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, informs its shareholders that its Extraordinary General Meeting (“EGM”) was held on Monday October 28, 2024 at 10:00 am in the offices of the Berquin law firm, 11 avenue Lloyd George, 1000 Brussels, in the presence of Simon Wheeler, Chairman of the Board of Directors. The number of shares held by shareholders present, rep...

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) today announces a strategic transformation project with H4Orphan aimed at creating a leader in idiopathic pulmonary fibrosis and accelerating the development of its multi-target drug candidate. Operational highlights The proposed Operation is part of the strategic transformation project between TheraVet and H4Orphan aimed at developing the H4Orphan's flagship clinical program in idiopathic pulmon...
Back to Newsroom